Medtronic InterStim On Track For Medicare Coverage After MCAC Review
This article was originally published in The Gray Sheet
Executive Summary
The Medicare Coverage Advisory Committee's Medical/Surgical Procedures panel gave wide discretion to the Health Care Financing Administration to determine whether Medtronic's InterStim sacral nerve stimulation (SNS) device for urinary incontinence should be reimbursed prior to, or following, surgery.
You may also be interested in...
Medtronic Incontinence Device Appears Set For Favorable MCAC Review
Medtronic's InterStim sacral nerve stimulation (SNS) device for urinary incontinence is apparently poised for the first favorable review by the Medicare Coverage Advisory Commission (MCAC), based on a technical assessment prepared by the Technology Evaluation Center (TEC) of the Blue Cross/Blue Shield Association.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.